CSL Ltd. PT receives Investment Bank Analyst Rating Update
By Oliver Gray Investing.com - The S&P/ASX 200 added 47.8 points or 0.7% to 6,993 during Monday’s trade, advancing for the fifth consecutive session as investors sought to buy...
The United States represents about half of the world market cap—the value of shares of all companies globally. While that may seem like a giant piece of the pie, international...
CSL Limited (CSL) is a biotechnology company engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. CSL provides a portfolio of life saving medicines, including those that treat hemophilia and immune deficiencies, as well as vaccines to prevent influenza. Its segments include CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. CSL’s products include HIZENTRA, PRIVIGEN, IDELVION, HAEMATE, KCENTRA, HAEGARDA, ZEMAIRA/RESPREEZA, FLUAD and FLUCELVAX.